依巴斯汀治疗慢性自发性荨麻疹的疗效和安全性  

Efficacy and Safety of Ebastine in the Treatment of Chronic Spontaneous Urticaria

作　　者：李晓红[1] 钱靖[1] 吴先伟[1] 

机构地区：[1]甘肃省人民医院皮肤科,甘肃兰州730000

出　　处：《中国医学文摘（皮肤科学）》2014年第2期67-68,共2页China Medical Abstracts(Dermatology)

摘　　要：目的观察双倍剂量的依巴斯汀和常规剂量依巴斯汀联合富马酸酮替芬片治疗慢性自发性荨麻疹的疗效和安全性。方法将受试者随机分为两组,治疗组予双倍剂量的依巴斯汀,对照组予常规剂量的依巴斯汀联合富马酸酮替芬片,观察两组的疗效和安全性,并进行统计学分析。结果治疗2周后治疗组和对照组有效率分别为90.00%和75.00%;4周后分别为93.33%和80.77%,疗效差异有统计学意义(P<0.05)。两组均未出现严重不良反应。结论双倍剂量的依巴斯汀治疗慢性自发性荨麻疹效果显著,不良反应轻,安全性高,值得临床应用。Objective To evaluate the efficacy and safety between double doses of Ebastine and single dose of Ebastine combined with Ketotifen fumarate in treatment of chronic spontaneous urticaria. Methods All the subjects were divided into two groups randomly. The treatment group was prescribed with double doses of Ebastine, the control group was prescribed with single dose of Ebastine and Ketotifen fumarate, and the results were statistically analyzed. Results The results showed that the effective rates were 90. 00% and 75.00% in the treatment and control group respectively after 2 weeks＇ treatment, while the figures were 93.33% and 80. 77% respectively after 4 weeks＇ treatment. There were significant difference （ P 〈 0.05 ） between the two groups about the effective rates. Conclusion A double dose of Ebastine in treatment of chronic spontaneous urticaria is an effective and safe method and it is worthy to spread in clinic.

关 键 词：依巴斯汀 慢性自发性荨麻疹 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]